Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Ovarian Cancer
Interventions
BIOLOGICAL

BC-819

"Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course."

Trial Locations (4)

Unknown

The Edith Wolfson Medical Center, Holon

Hadassah University Hospital, Jerusalem

Meir Hospital, Kfar Saba

Sheba Medical Center, Tel Litwinsky

All Listed Sponsors
lead

Anchiano Therapeutics Israel Ltd.

INDUSTRY

NCT00826150 - Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer | Biotech Hunter | Biotech Hunter